Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907114 | 0.90 | PTGS2 (0.48) | PTGS2PTGS1NR1I2MEN1KMT2A | |
| SCHEMBL1991595 | 0.87 | NR3C1 (0.47) | PTGS2PTGS1NR1I2SMN1; SMN2 | |
| SCHEMBL1989553 | 0.84 | HTR6 (0.51) | PTGS2PTGS1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1993889 | 0.83 | PTGDR2 (0.54) | — | |
| SCHEMBL1989421 | 0.82 | NPC1 (0.44) | PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL4150829 | 0.82 | LMNA (0.43) | PTGS2PTGS1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1992064 | 0.81 | PTGDR2 (0.39) | PTGS2NR1I2MEN1KMT2A | |
| SCHEMBL1989562 | 0.81 | PTGS2 (0.45) | PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL10277289 | 0.80 | LMNA (0.43) | PTGS2PTGS1LMNANR1I2HTT | |
| SCHEMBL2909420 | 0.79 | TSHR (0.46) | PTGS2PTGS1LMNANR1I2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415394-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (GB) | 2013-04-09 | — | — | US | disclosed |
| US-8349897-B2 | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | ASTRAZENECA AB (SE) | 2013-01-08 | — | — | US | disclosed |
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | LUKER TIMOTHY JON (GB) | 2012-07-12 | — | — | US | disclosed |
| EP-1937633-B8 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| EP-1937633-B1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| EP-1937633-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | Astra Zeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039741-A1 | BIPHENYLOXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178814-A1 | Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease | BPGM, PPARA, HPD | PTGS2 1220/4885PTGS1 1276/4885LMNA 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.